The goal of this study was explore the role of indoleamine 2, 3-dioxygenase (IDO) in the therapeutic effect of probiotics on inflammatory bowel disease (IBD). Trinitrobenzene sulfonic acid (TNBS) was used to induce colitis in mice and 1-methyltryptophan (1-MT) to block expression of IDO. Clinical manifestations and macroscopic and microscopic colonic changes were assessed using a disease activity index (DAI), the Wallace-Keenan, and Curtner scoring systems, respectively. Expression of colonic IDO was detected by western blot. Immunohistochemistry analysis to evaluate numbers of CD11c þ cells and expression of IL-17 and Foxp3 showed that DAI, Wallace-Keenan, and Curtner scores were lower in the Bifidobacteria treatment group than the control group and that the therapeutic effect of Bifidobacteria was blocked by 1-MT (P < 0.05). Additionally, Bifidobacteria were found to increase expression of IDO and the numbers of CD11c Key words Bifidobacteria, inflammatory bowel disease, indoleamine 2, 3-dioxygenase.
Indoleamine 2, 3-dioxygenase, the rate-limiting enzyme in tryptophan catabolism within the kynurenine pathway, is primarily expressed on antigen-presenting cells, such as DCs, and is widely distributed in the body, including in the placenta, colon, lymph nodes, spleen, lungs and kidneys. Munn et al. observed that IDO is strongly expressed in placenta and that inhibition of IDO expression leads to the abortion of the fetus, suggesting that IDO plays an important role in immune suppression during pregnancy (1) . Numerous studies have subsequently been conducted on IDO and its role in immune regulation. Regulation of IDO activity is now recognized as a potential new approach to treating immune-related diseases.
Inflammatory bowel disease is a chronic, nonspecific, intestinal inflammatory disease, the pathogenesis of which is unclear. It has been shown that intestinal bacteria are closely associated with pathogenesis of IBD: IL10 À/À mice do not develop colitis under gnotobiotic conditions (2) . The composition of intestinal bacteria in individuals with IBD reportedly differs significantly from that of healthy individuals (3) . Duchman et al. have shown that antigens from the intestinal microflora can induce proliferation of T cell clones isolated from patients with active IBD, but not of T cells from individuals without IBD, suggesting that intolerance to gut bacteria may be lost in patients with active IBD (4) . Recent studies have shown that probiotics may be a promising therapy for IBD, results of both human and animal experiments showing that probiotics can relieve the symptoms of IBD. However, although many studies have been performed, the mechanism(s) by which probiotics relieve IBD symptoms remains unclear.
Previous studies have demonstrated that IDO not only degrades tryptophan, but also plays an important role in immune regulation, including inhibiting the proliferation and enhancing the regulatory function of T cells (5, 6) . In addition, it has been shown that IDO plays an important role in immune regulation of interactions between the host and microorganisms. Gastric biopsy specimens from individuals with Helicobacter pylori infection contain significantly greater amounts of IDO than specimens from individuals without this infections. Activation of IDO can increase production of tryptophan metabolites, such as kynurenine, which has been shown to inhibit the Th1 and Th17 immune response and the unregulated Th2 pathway, eventually attenuating inflammation caused by H. pylori (7) . In another study, liver inflammation caused by Rhodococcus equi was more severe in IDO-deficient mice than in control animals. Liver tissue from IDO (À/À) mice had higher inflammation scores, weaker expression of transforming growth factor-b and FOXP3 than did control mice (8) . In addition, IDO can inhibit the inflammation caused by infections of Listeria monocytogenes, Toxoplasma, Staphylococcus aureus and other pathogens.
We hypothesized that IDO plays an important role in the interaction between probiotics and the intestinal immune system. The aim of this study was to investigate the role of IDO in the therapeutic effect of probiotics on IBD.
MATERIALS AND METHODS

Strains
Live Bifidobacterium preparations (Livzon, Zhuhai, Guangzhou) dissolved in 0.9% NS (every preparation contained 5 Â 10 7 Bifidobacteria) were used in this study.
Animals
Six to eight weeks old female BALB/c mice were maintained in a specific pathogen-free facility for 7 days before the experiment was initiated. The experiment was performed in two steps. In the first step, BALB /c mice were randomly allocated to three groups (n ¼ 8): a TNBS, TNBS þ Bifidobacteria and control group. In the second step, there were five groups: a TNBS, TNBS þ Bifidobacteria, TNBS þ Bifidobacteria þ 1-MT, 1-MT and control group. Seven days before the experiment, the TNBS þ Bifidobacteria and TNBS þ Bifidobacteria þ 1-MT groups received 1 Â 10 8 CFU of Bifidobacteria in 0.2 mL of 0.9% NS by gavage once a day, whereas the other groups received 0.2 mL of 0.9% NS without Bifidobacteria. A solution containing 50% ethanol and 2.5 mg TNBS was administered as an enema to the TNBS þ Bifidobacteria and the TNBS þ Bifidobacteria þ 1-MT groups on the day of the inoculation (0.1 mL/mouse), whereas the other groups received 50% ethanol. The TNBS þ Bifidobacteria and the TNBS þ Bifidobacteria þ 1-MT groups were intraperitoneally injected daily with 10 mg of 1-MT. Clinical manifestations were scored using the DAI (9), and colonic macroscopic changes were assessed by the WallaceKeenan scoring system (10) . The Curtner scoring system was used to assess microscopic damage (11) .
Immunohistochemistry and immunofluorescence
After conventional deparaffinization, antigen retrieval was performed by incubating samples in a sodium citrate solution (PH 6.0) in 95°C water for 40 min; endogenous peroxidase was blocked with 3% H 2 O 2 . Sections were incubated with anti-IDO(1:100; Abcam, Cambridge, MA, USA), anti-IL-17 (1:500; Abcam) and anti-Foxp3 (1:300; Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies at 37°C for 45 min and then incubated with ChemMate Envision þ HRP (Dako Envision; Dako, Carpinteria, CA, USA) at 37°C for 45 min. Finally, the immunoreaction was ended with a 3,3'-diaminobenzidine-tetrachloride ready-to-use commercial solution and samples were counterstained with hematoxylin.
For immunofluorescence double staining, the sections were stained with rat anti-mouse monoclonal anti-IDO (1:40; Abcam) and guinea pig anti-mouse CD11c (1:40; Santa Cruz Biotechnology) overnight at 4°C. After staining samples with secondary antibodies, tetramethylrhodamine-labeled goat anti-rat IgG (1:200; Jackson Immunoresearch, West Grove, PA, USA), or Alex fluora 488 goat anti-guinea pig IgG (1:400; Jackson Immunoresearch) for 2 hr at room temperature. The sections were then counterstained with 4',6'-diamidino-2-phenylindole dihydrochloride.
The immunoreaction of IDO was analyzed with ImagePro-Plus 6.0 and integral optical density calculated in ten high-power fields for each mouse. The fluorescence images were taken with a Zeiss LSM 710 confocal microscope (Zeiss, Oberkochen, Germany). The number of cells was counted with ZEN 2012 software.
Western blot
Total protein was prepared from colonic tissues and protein assays (KeyGEN, Nanjing, China) performed.
The samples were denatured and separated on a 10% SDS-PAGE gel. After electrophoresis, the separated proteins were transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membranes were incubated with either a 1:200 dilution of an anti-IDO antibody (Abcam) or a 1:1500 dilution of an anti-glyceraldehyde 3-phosphate dehydrogenase antibody (ZSGQ-BIO, Beijing, China) for primary antibodies followed by two secondary antibodies including peroxidase-conjugated AffiniPure Goat anti-Rabbit IgG (1:20,000; ZSGQ-BIO) and peroxidase-conjugated AffiniPure Goat anti-Mouse IgG (1:20,000; ZSGQ-BIO). Proteins were detected using ECL (ZSGQ-BIO, Beijing, China).
The films were analyzed by Quality One 4.6.2 software and the ratio of IDO/glyceraldehyde 3-phosphate dehydrogenase was calculated to compare expression of colonic IDO between groups.
Statistical analyses
Statistical analyses were performed using SPSS 19.0 statistical software. Comparisons among groups were made with anova and Tukey's test. Data are presented as the means AE SE. P < 0.05 was considered to denote significance.
RESULTS
Bifidobacteria alleviate TNBS-induced colitis
Mice receiving TNBS gradually developed weight loss, diarrhea and bloody stools. We observed mucosal hyperemia, edema and ulceration when we dissected their colons and colonic mucosal hyperemia, edema, ulceration and inflammatory cell infiltration when we examined them under the microscope. Mice that had received Bifidobacteria had milder inflammation than those that only received TNBS. DAI scores (P < 0.05), Wallace-Keenan scores (P < 0.05) and Curtner scores (P < 0.05) were lower in the TNBS þ Bifidobacteria group than in the TNBS group (Fig. 1) .
Bifidobacteria increase expression of colonic IDO
Immunohistochemistry analysis showed expression of IDO in the colonic epithelium and lamina propria. Immunofluorescence analysis further demonstrated that most of the IDO-positive cells in the lamina propria also express CD11c. The integral optical density was much higher in the TNBS þ Bifidobacteria than the TNBS group (85255.0 AE 38861.5 vs. 48582.5 AE 7359.8, P < 0.05) (Fig. 2a) . Western blot showed that colonic IDO expression was stronger in the TNBS þ Bifidobacteria than the TNBS group (P < 0.05) (Fig. 2b) .
Bifidobacteria up-regulates DCs and stimulates DC-induced IDO expression Dendritic cells, which are considered important antigenpresenting cells, stimulate Treg cells differentiation by inducing IDO expression (12) . We found more numerous CD11c þ cells in the lamina propria of mice receiving TNBS þ Bifidobacteria had in that of the mice that only received TNBS (P < 0.05) (Fig. 3a,b) . Double-staining revealed that most of the CD11c þ cells also express IDO. There were more double stained cells in the TNBS þ Bifidobacteria than in the TNBS group (P < 0.05) (Fig. 3c,d ).
1-MT blocks the therapeutic effect of Bifidobacteria
We next tested whether blocking expression of IDO attenuates the therapeutic effect of Bifidobacteria. 1-MT, a competitive inhibitor of IDO that has been widely used in animal and clinical trials, acts as a Trp-mimetic to reverse the immunosuppressive action of IDO-induced Trp insufficiency and inhibits IDO enzyme activity (13-15).
We found higher DAI scores in the mice in the TNBS þ Bifidobacteria þ 1-MT group than in those in the TNBS þ Bifidobacteria group (P < 0.05). We observed slight weight loss and occasional stool changes without bloody stools in the 1-MT and control groups. There was no significant difference in DAI scores between the 1-MT and control groups (P > 0.05) (Fig. 4a) .
Colonic inflammation was worse in the TNBS þ Bifidobacteria þ 1-MT than in the TNBS þ Bifidobacteria group (P > 0.05); however, there was no significant difference in colonic inflammation between the 1-MT and control group. Wallace-Keenan scores were as follows: control group: 0.45 AE 0.09; TNBS group: 3.32 AE 0.34; the TNBS þ Bifidobacteria group: 2.34 AE 0.28; TNBS þ Bifidobacteria þ 1-MT group: 3.57 AE 0.34; and 1-MT group: 0.78 AE 0.17 (Fig. 4b) .
Microscopically, inflammation was more severe in the TNBS þ Bifidobacteria þ 1-MT group than in the TNBS þ Bifidobacteria group (P < 0.05); however, there was no significant difference between the 1-MT and control groups. Curtner scores were as follows: control group: 0.75 AE 0.15; TNBS group: 4.25 AE 0.48; TNBS þ Bifidobacteria group: 2.50 AE 0.24; TNBS þ Bifidobacteria þ 1-MT group: 0.48 AE 0.51; and 1-MT group: 0.85 AE 0.12 ( Fig. 4c,d ).
Bifidobacteria up-regulate expression of Treg cells and down-regulate Th17 cells in TNBS-induced colitis.
Studies have shown that expression of Th17 and Treg cells is crucial for immune homeostasis. We investigated whether Bifidobacteria regulate the balance between the 
number of Th17 cells and Treg cells and found more numerous Foxp3
þ Treg cells in mice in the TNBS þ Bifidobacteria group than in those in the TNBS group (P < 0.05) (Fig. 5a) . Furthermore, there were fewer Foxp3 þ Treg cells in the TNBS þ Bifidobacteria þ 1-MT group (P < 0.05) (Fig. 5a ). These data indicate that Bifidobacteria up-regulate Foxp3 þ Treg cells by inducing IDO expression.
In contrast, the TNBS þ Bifidobacteria group had fewer IL-17 þ T cells than the TNBS group and 1-MT did not change expression of IL-17 (P < 0.05) (Fig. 5b) .
DISCUSSION
The pathogenesis of IBD remains unclear; however, genetic factors, intestinal bacteria, the immune system and environmental factors may be involved. Among these factors, intestinal bacteria have attracted a great deal of attention. They not only play an important role in the pathogenesis of IBD, but are also used to treat IBD, many studies having demonstrated that probiotics are a promising therapy for this condition. Kim et al. have reported that Bifidobacterium bifidum prevents experimentally induced colitis in mice by inhibiting T cell activation (16). Gao et al. have demonstrated that Lactobacillus reuteri suppresses intestinal inflammation in TNBS-induced mouse colitis (17) . In a randomized, double-blind, placebocontrolled study, researchers observed that synbiotic consumption improves the Crohn disease activity index in patients with active Crohn disease (18) . Our study has also shown that Bifidobacteria attenuate TNBS-induced colitis.
How probiotics alleviate intestinal inflammation is unclear. However, studies have shown that probiotics can: (i) inhibit growth of pathogenic bacteria by competing for nutrients or producing antibacterial substances (19, 20) ; (ii) enhance intestinal mucosal barrier function (13); and (iii) regulate mucosal immune responses (14) . In our study, intestinal IDO expression was stronger in the group treated with Bifidobacteria and 1-MT blocked the protective effect of Bifidobacteria on TNBS-induced colitis, suggesting that induction of IDO expression in the intestinal mucosa may be one of the mechanisms by which probiotics alleviate inflammation associated with IBD. Under normal conditions, expression of IDO in the gastrointestinal tract is very weak; however, it is significantly upregulated after stimulation by inflammatory cytokines, such as IFN-g, TNF-a and IL-1B (21, 22) . Studies have shown that IDO expression is significantly increased in patients with active IBD (23, 24) . Animal experiments have also shown that IDO expression is increased in TNBSinduced colitis and that inhibition of IDO expression results in more severe inflammation (25) . These data suggest that IDO plays an important role in immune regulation in the pathogenesis of IBD. IDO activates the general control nonderepressible 2 signaling pathway and inhibits mammalian target of rapamycin and protein kinase Cu pathways by reducing the local concentration of tryptophan (26) , whereas the metabolite of tryptophan (kynurenine) can activate aryl hydrocarbon receptor and exert an immunosuppressive function. Changes in these pathways can promote differentiation of regulatory T-cells and inhibit effector T-cell function. Activation of IDO in antigen-presenting cells also directly inhibits the function of effector T-cells by promoting Th2 cell polarization and inducing cell-cycle arrest and apoptosis of these cells.
Dendritic cells play an important role in presenting antigens and stimulating primary immune responses. Our data indicate that Bifidobacteria promote differentiation of CD11c þ cells and stimulate them to produce IDO. This finding is consistent with previous reports. One study found that the mixture of probiotics designated IRT5 generates CD11c þ DCs, which strongly express IL-10, transforming growth factor-b, COX-2 and IDO, and converts (þ) DCs and reducing differentiation/expansion of Th1 and Th17 cells (28) . Macho et al. observed that peptidoglycan purified from Lactobacillus salivarius reduces experimental colitis by promoting development of tolerogenic (CD103þ) DCs and regulatory T cells, accompanied by an increase in amounts if IDO (29) . Our data further confirm that generation of Foxp3 þ Treg cells by Bifidobacteria is dependent on expression of IDO.
Overall, our results indicate that Bifidobacteria attenuates TNBS-induced colitis and that its therapeutic effect is blocked by 1-MT. In addition, Bifidobacteria promote differentiation of CD11c þ cells and stimulate them to produce IDO. Induction of IDO expression, which up-regulates Foxp3 þ Treg cells in the intestinal mucosa, may be one of the mechanisms by which probiotics alleviate TNBS-induced colitis.
